Allogene Therapeutics: Q4 Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $85.8 million in its fourth quarter.

The South San Francisco, California-based company said it had a loss of 51 cents per share. Losses, adjusted for asset impairment costs, were 43 cents per share.

The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.

The immuno-oncology company posted revenue of $21,000 in the period, meeting Street forecasts.

For the year, the company reported that its loss narrowed to $327.3 million, or $2.09 per share. Revenue was reported as $95,000.

In the final minutes of trading on Thursday, the company's shares hit $4.50. A year ago, they were trading at $5.61.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO